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Background: Assessment of design heterogeneity conducted prior to meta-analysis is infrequently reported; it is
often presented post hoc to explain statistical heterogeneity. However, design heterogeneity determines the mix of
included studies and how they are analyzed in a meta-analysis, which in turn can importantly influence the results.
The goal of this work is to introduce ways to improve the assessment and reporting of design heterogeneity prior
to statistical summarization of epidemiologic studies.
Methods: In this paper, we use an assessment of sugar-sweetened beverages (SSB) and type 2 diabetes (T2D) as an
example to show how a technique called ‘evidence mapping’ can be used to organize studies and evaluate design
heterogeneity prior to meta-analysis.. Employing a systematic and reproducible approach, we evaluated the following
elements across 11 selected cohort studies: variation in definitions of SSB, T2D, and co-variables, design features and
population characteristics associated with specific definitions of SSB, and diversity in modeling strategies.
Results: Evidence mapping strategies effectively organized complex data and clearly depicted design heterogeneity.
For example, across 11 studies of SSB and T2D, 7 measured diet only once (with 7 to 16 years of disease follow-up),
5 included primarily low SSB consumers, and 3 defined the study variable (SSB) as consumption of either sugar or
artificially-sweetened beverages. This exercise also identified diversity in analysis strategies, such as adjustment for
11 to 17 co-variables and a large degree of fluctuation in SSB-T2D risk estimates depending on variables selected
for multivariable models (2 to 95% change in the risk estimate from the age-adjusted model).
Conclusions: Meta-analysis seeks to understand heterogeneity in addition to computing a summary risk estimate.
This strategy effectively documents design heterogeneity, thus improving the practice of meta-analysis by aiding in: 1)
protocol and analysis planning, 2) transparent reporting of differences in study designs, and 3) interpretation of pooled
estimates. We recommend expanding the practice of meta-analysis reporting to include a table that summarizes design
heterogeneity. This would provide readers with more evidence to interpret the summary risk estimates.
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Meta-analyses, which are quantitative methods for pooling
results from epidemiologic studies, inform research prior-
ities and health policy. Combining similar studies asking a
similar research question is fundamental to the interpret-
ability of summary risk estimates [1]. Combining results
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An assessment of the similarity of studies (that is, design
heterogeneity) is a fundamental element of a meta-analysis
of epidemiological studies [3-8]. There are two major
types of heterogeneity: statistical heterogeneity and
design heterogeneity (sometimes referred to as clinical
and methodological diversity) [9]. Statistical heterogeneity
is purely a mathematical assessment; evidence of statistical
heterogeneity indicates that there is greater statistical vari-
ance between the study results than would be expected byLtd. This is an Open Access article distributed under the terms of the Creative
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Design heterogeneity, in contrast, involves the extent to
which the studies being considered for inclusion in a
meta-analysis differ in study design, including population
studied, specificity of exposure measurement, uniformity
of diagnostic criteria (in the outcome), confounders mea-
sured, concomitant exposures measured, and statistical
models [3,7].
Reviews of the practice of meta-analysis in observa-
tional epidemiology have observed that investigators
often emphasize the summarization function over the
assessment of heterogeneity [2,11]. Additionally, in a
systematic overview of meta-analyses, we found fewer
than a third of 47 eligible meta-analyses of lifestyle and
dietary risk factors for type 2 diabetes (T2D) reported a
detailed characterization of design heterogeneity that
was used to guide the quantitative pooling of study
results (manuscript in preparation). In contrast, more
than 90% of the meta-analyses reported some assessment
of statistical heterogeneity (Q statistic or I2 index). These
observations illustrate that the assessment of design
heterogeneity frequently occurs after statistical hetero-
geneity has been identified. In practice, design hetero-
geneity assessment would be informative if undertaken
before any quantitative summarization takes place [2].
In 2013, two journals focusing on research synthesis
methods (Systematic Reviews and Research Synthesis
Methods) emphasized the importance of qualitative evalu-
ation of studies selected for meta-analysis, calling for more
strategies to aid conduct and reporting [12,13]. In this
paper, we present a strategy for objectively and transpar-
ently characterizing design heterogeneity of epidemiologic
studies prior to meta-analysis.Methods
Evidence-based mapping was used as a tool to diagram
and tabulate data across a group of studies selected for
meta-analysis, with the following three primary objectives:
1. to document differences in exposure (intervention),
comparator, outcome, and study design and population
characteristics;
2. to assess the design features and population character-
istics associated with specific definitions of the exposure
(intervention), comparator and outcome; and
3. to evaluate the diversity in modeling strategies (for
example, assessment of confounding for observational
epidemiology studies) and suggest simple summary mea-
sures to benchmark susceptibility of the exposure risk
estimate to the influences of included (and excluded)
co-variables in multivariable regression models.
We sought to summarize the detailed work of multiple
evidence maps created to meet these objectives into a
single table with a universal adaptable format. The aimof this table is to facilitate the reporting of design hetero-
geneity, which is fundamental to developing a protocol,
analyzing data, and interpreting meta-analyses.
Tools
Evidence maps are a relatively new tool used to transpar-
ently generate a clear visual depiction of complicated data,
either in the form of a diagram or a table [14]. Evidence
maps have been used to set research priorities by display-
ing existing research landscapes without linking study
designs to study results [14-23]. Precisely because evidence
mapping seeks to organize studies without summariz-
ing results, they are natural tools for assessing design
heterogeneity prior to meta-analysis. Therefore, we ex-
panded evidence mapping methods by demonstrating
their usefulness in planning a meta-analysis. This work
is guided by previously published evidence maps whose
focus was research priority setting [14-23] and the existing
standards for conducting and reporting of systematic
reviews of observational research [4,24]. Evidence maps
were created in Excel (Microsoft, Redmond, Washington,
USA); however, it is possible to conduct the work using
other database software.
Definition of design heterogeneity
In this paper, design heterogeneity refers to diversity across
studies in sociodemographic and health characteristics of
the populations studied; methods of study execution and
data ascertainment; exposure (intervention), comparator
and outcome definitions; and statistical approaches, as
well as analyses conducted and reported.
Evidence-based mapping framework: steps for evaluating
design heterogeneity
In order to present the evidence-based mapping frame-
work in a way that other investigators can easily translate
to their own research questions, the next section describes
each step generally. The details of the application of
the framework to a specific example are described in
the subsequent section, including the systematic search
process. This framework is designed to be dynamic.
Although we recommend completing this work prior to
finalizing a protocol and analysis plan for a meta-analysis,
updating will be necessary when new data become avail-
able. We recommend that at least three investigators thor-
oughly use this framework: an author to abstract data at
the onset and another to verify accuracy and a consensus
of experts to review completed maps and evaluate aspects
of design heterogeneity that may importantly influence
meta-analysis of the selected studies.
Prior to applying this three-step framework, a PICO
(participants, intervention (or exposure), comparator, and
outcome) table is completed to identify key research com-
ponents and to develop/clarify the research question
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meta-analysis, diversity is assessed across all included
studies for each of the four PICO elements. An evaluation
of confounding is added when including observational
studies in the analysis. This framework can be used to
document design heterogeneity across many study types,
including randomized clinical trials.
Step 1: To assess diversity across selected studies for each
participants, exposure/intervention, comparator, and
outcome element
The goal of the first step of this framework is to evaluate
the extent of diversity within each of the four PICO
elements, although not in the same order. The frame-
work begins with an assessment of the exposure variable
(or intervention) across selected studies for two reasons:
the exposure definition often is the driver of the analysis,
and it is usually documented in the most detail in a
publication.
For each study, the definition used for exposure is
abstracted, including information on the measurement
tools, timing of variable collection, and method/criteria
(self-report, interviewer administered, medical or bio-
chemical test). When possible, the exact language used to
ascertain exposure status or details of the test performed is
recorded. A diagram (evidence map) is created to describe
how definitions of the study variable related to one another,
quantitatively and qualitatively. The description of the
variable definition, using the original language from the
publication as much as possible, is summarized in a text
box. Text boxes are organized to group together exposure
variables with similar definitions. Similar definitions are
physically grouped together in the diagram, and the
review investigator assigns descriptive ‘category headings’
accordingly. The category of the exposure variable most
frequently employed across studies is placed at the top of
the diagram, with other categories arranged in order of
decreasing frequency. An evaluation of whether the most
frequently used definition is indeed the most appropriate
definition was not undertaken at this point in the review
process. The step should be examined later along with
study quality and risk of bias.
The resulting map visually depicts patterns within the
exposure definitions and is used to preliminarily evaluate
whether the collective group of studies directly address
the review question or address more than one distinct
question. It also facilitates an initial assessment of fre-
quently occurring subgroups of the exposure variable,
which could be considered for stratified or sensitivity
analyses in a meta-analysis.
In an etiologic example, the comparator is often the
lowest exposure category and therefore included as part
of the evaluation of the study variable. In analyses of
randomized trials or nonrandomized studies, step 1 isrepeated in order to evaluate diversity among definitions
of the comparator across selected studies.
Step 1 is also repeated for the outcome variable (with
particular attention to diagnostic method/criteria) and as
needed for variables describing the study characteristics
and population, examples include study location/ethnicity,
gender, study size, study duration, timing of participant
assessments, and baseline population characteristics such
as age, body size, or health status. Univariate statistics
(n, median, proportion, range) were used to describe
the diversity of variable definitions (exposure, outcome,
and co-variables) across included studies.
Step 2: To assess the design features and population
characteristics associated with specific definitions of the
exposure
The second step is to assess whether specific definitions
of the exposure variable tended to aggregate with specific
study design features or population characteristics. Using
separate diagrams for each category of the exposure vari-
able (identified in Step 1), important design features
and population characteristics are listed for each study
and qualitatively inspected to identify emerging patterns.
Particular attention is focused on differences between
categories of the exposure variable that are identified in
Step 1 as potentially not directly answering the review
question. Likewise, among exposure categories from studies
directly answering the review question, the aggregation of
study design/population characteristics is used to augment
decisions from Step 1 about stratified/sensitivity analyses in
a future review/meta-analysis.
Step 2 can be repeated as necessary to understand
whether certain comparators or outcomes are associated
with design or population characteristics.
Step 3: To evaluate the diversity in multivariable modeling
strategies and assessment of confounding
The aim of step 3 is to evaluate co-variables selected for
models by primary studies and to facilitate the selection of
an adequately adjusted model or models for combining
by meta-analysis of observational studies. Evidence-based
mapping is used to visually display the patterns of co-
variables adjusted for in each model as reported by each
publication. A table summarizes how the exposure vari-
able is analyzed in each study (for example, continuous
measure or categories) and tallies the number of models
from each publication and the number of covariates
adjusted for in each model.
Every regression model is listed in sequential order as
presented in the original research publication and a check-
list format is used to summarize covariates adjusted for in
each model. Covariates most frequently adjusted for in
multivariable models across all studies are listed in the
map header. A check denotes inclusion of a covariate
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timing of the measurement of the covariate (for example,
BL for baseline). Less frequently adjusted covariates are
listed in a single column of the table.
For each multivariable model, the percent change in
the exposure-outcome risk estimate from the age-adjusted
model is calculated using the following equation:
(age-adjusted relative risk - multivariable adjusted rela-
tive risk)/(age-adjusted relative risk - 1).
This provides a quantitative assessment of the degree
of fluctuation in the exposure-response risk estimate
from the age-adjusted value, depending on the covariates
included in a model.
Frequency (n), median, proportion, and range are
used to describe across included studies the diversity
in definitions of the study variable used for analysis
(for example, how categories of exposure were defined),
number of multivariable models presented, number of
covariates adjusted for in multivariable models, and change
in exposure-outcome risk estimate from the age-adjusted
risk estimate.
Summarization of evidence-based mapping efforts
A single table, organized with sections for each PICO
element, captures important findings and bridges the
more practical need to concisely document and report
design heterogeneity. We adopted a format that would
be flexible for summarizing the large amounts of com-
plex data organized by evidence maps. Using cohorts as
the unit of analysis, for each major category of exposure
(as determined by Step 1), the following were summarized:
the distribution of important design and population char-
acteristics (as determined in Step 2: n, percent), operatio-
nalization of the study variable in the multivariable model
(Step 3: n, percent), the number of multivariable models
presented in the original publication (Step 3: median,
range), the number of covariates in multivariable models
(Step 3: median, range), and the change in exposure-
outcome risk estimate from the age-adjusted risk estimate
(Step 3: median, range).
Illustration of method using prospective observational
studies of sugar-sweetened beverages and type 2 diabetes
We illustrate the utility of an evidenced-based mapping
framework using an example from nutritional epidemi-
ology: sugar-sweetened beverages (SSB) and type 2 diabetes
mellitus (T2D). This example is ideal for illustrating this
framework, because studies of this relationship characteris-
tically have considerable variability in study design.
Selection criteria
First, we identified published work for the example. We
used an electronic search strategy to identify all cohort
studies of dietary sugar intake and T2D. Published researchthat met the following inclusion criteria were identified
for full text review: 1) a prospective observational study
(that is, dietary sugar consumption was measured in
chronologic time prior to measurement of T2D) and 2)
a study analyzing the risk of T2D associated with dietary
sugar intake, dietary patterns, or glycemic load/index. To
address the possibility that electronic search strategies
might omit publications of findings not important enough
(for example, null findings) for inclusion in the title,
keywords, or abstract, our search ascertained published
research on dietary patterns as well as dietary sugar
intake. Additionally, we identified reviews and meta-
analyses of epidemiologic studies on this topic in order
to examine their reference lists.Systematic search
We conducted database searches of PubMed and Scopus
(inception to 10 March 2014). We limited our search of the
PubMed database to human studies and English language
publications, and used the following combination of
search terms and medical subject headings (inception
to 19 September 2013: 2,005 titles): sweetening agents,
energy intake, calories, caloric intake, fructose, glucose,
sucrose, monosaccharides, disaccharides, dietary carbo-
hydrates, soda, sugar beverage, sweetened beverage, soft
drink, dietary sugar, juice, sugar intake, sugary foods,
sweets, sweet foods, carbohydrate intake, glycemic index,
glycemic load, macronutrients AND diet, dietary patterns,
dietary intake AND cohort studies, incidence, follow-up,
prospective studies, meta-analysis AND Diabetes Mellitus,
type 2 diabetes). We conducted a similar title, abstract,
and keyword search of the Scopus database (1,143 titles):
(diet* and sugar*) OR (diet* and pattern*) OR soda OR
juice OR (sweet* and drink*) OR (sweet* and beverage*)
OR (sweet* and food*) and (‘type 2 diabetes’). The search
results were downloaded into Refworks (©Proquest 2012).
Titles, abstracts, and keywords of all articles were exam-
ined, and those that continued to meet the inclusion
criteria were ascertained for further full text review.
To ensure accurate identification of eligible studies, we
conducted two pilot tests of our methodology prior to
implementing the search described above. First, we assessed
and revised a search strategy after retrieval and review of
citations from several years, 2010 to 2013. The revised
search strategy included more terms and more specific
terms for dietary sugar, glycemic load/index and energy
intake. This led to a broader, more inclusive search and the
review of more titles. Second, two authors independently
reviewed a subset of citations identified by our search strat-
egy for eligibility (titles from 2012). Because both authors
identified the same articles (inter-rater reliability = 100%),
decisions regarding inclusion/exclusion reliably were based
on a review by one author.
Figure 1 Systematic search for eligible studies of dietary sugar intake and type 2 diabetes. (a) 2,005 from PubMed and 1,143 from Scopus
data base searches. (b) Titles remotely on topic were screened twice. (c) We completed a full-text review of all studies of dietary patterns, glycemic load/
index, and carbohydrates to assess whether a measure of dietary sugar was examined individually. We also reviewed the full text and bibliographies of
studies of sugar-sweetened beverages (SSB), juices, sugars, macronutrients and key reviews and commentary. (d)We identified three cohorts with multiple
publications, from which we selected for this synthesis the one publication in which SSB was either the main study variable or the definition was the
clearest. We identified two publications of the Health Professionals Follow-up study (HPFS); of these two publications, the one that assessed SSB as the
primary study variable was selected for inclusion [34] and the other that presented analyses stratified by the main variable, caffeine consumption, was
excluded [35]. We selected one of the three publications from the Nurse’s Health Study (NHS). Bazzano and coworkers [39] reported risk separately for
a one-increment serving of sugar-sweetened colas, fruit punch, low calorie cola, and other carbonated beverage. In a personal communication from a
2010 meta-analysis [50], Malik and coworkers report a risk estimate for SSB intake, but the definition was not provided nor was the analysis adjusted for
age. Although not ideal, the Bhupathiraju et al. analysis of SSB, stratified by caffeinated and caffeine-free beverage consumption, provides a clear definition
(sugar-sweetened carbonated beverages) and analysis, and therefore was selected for inclusion in this paper [35]. Our final exclusion was a 2013 publication
of EPIC-France [31], from which all participants were represented by an included EPIC publication [29].
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A flow chart tracked eligible publications identified by the
literature searches and illustrated a two-stage evaluation
process (Figure 1).
As part of the process of identifying eligible cohorts
we displayed how epidemiologic studies of SSB fit into
the broader field of research on dietary sugar intake and
T2D. We tabulated the cohorts that published on measures
of dietary sugar intake (including SSB) by study size. The
number of publications and corresponding cohorts were
depicted for each definition of dietary sugar intake, includ-
ing sweetened beverages and macronutrients (sucrose,
fructose, and glucose). Table 1 was based on the World
Health Organization and the Food and AgriculturalTable 1 Publications and cohorts that report the relationship be
Cohorts (reference) Sugar-sweetened beverages
















10,000 TO 24,999 Participants
ARIC [44] √
5000 to 9,999 Participants
MESA [45] √





Total unique cohorts representedc 11
9 Publications: 8 Cohorts
aSSB was broadly defined to include studies that defined sweetened beverages as e
bTotal sugars = disaccharides and monosaccharides.
cTotal cohorts represented enumerates unique cohorts. Eight of 10 countries are re
except for Norway and Greece.
ARIC, Atherosclerosis Risk in Communities Study; WHS, Women’s Health Study (B, Bl
(InterAct Study, Potsdam, Norfolk, Netherlands, France); FMC, Finnish Mobile Clinic H
Study of Japanese factory workers; JPHC, Japan Public Health Center-based Prospec
Study; SCHS, Singapore Chinese Study.Organization of the United Nations definitions [26] of diet-
ary sugar intake as ‘all monosaccharides and disaccharides
added to foods by the manufacturer, cook, or consumer;
sugars naturally present in honey, syrups and fruit juices
[27].’ Table 1 facilitated identifying the studies that focus on
SSB as a subset of all studies on dietary sugar intake.
Data abstraction
For eligible prospective observational studies of SSB and
T2D, we created detailed data abstraction tables. For
each study, we abstracted data on sample size and popu-
lation characteristics (for example, country, baseline
age and body size), SSB definition and consumption at
baseline, T2D diagnosis, dietary assessment timing andtween measures of dietary sugar intake and type 2 diabetes
Macronutrients







√ √ √ √
√ √ √ √
√ √ √ √ √
6 6 5 5 1
4 6 5 5 1
ither SSB only or as soft drinks (either sugar or artificially sweetened).
presented in EPIC-All, which overlaps with country specific EPIC publications
ack, I, Iowa); EPIC-All, P, N, NL, FR, European Prospective Investigation of Cancer
ealth Examination Survey; HPFS, Health Professional’s Follow up Study; Jfact,
tive Study; MESA, Multi-ethnic Study of Atherosclerosis; NHS, Nurse’s Health
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beverage consumption, variables included in multivari-
able models, and statistical analyses. We present this
work without linking study design features to study
results. We recommend this step in order to minimize
as much as possible selection bias when planning a
protocol for a subsequent meta-analysis. One author
abstracted data at the onset, all authors contributed to
strategy and map designs, and another author verified
the accuracy of data abstracted at the end stage.
Participants, exposure/intervention, comparator, and
outcome elements
The following PICO elements were specified for this work:
1. Participants/study design: adults from the general
population without T2D/prospective observational
studies.
2. Exposure: sugar-sweetened beverage consumption
(our example is etiologic; therefore the ‘I’ in PICO is
exposure).
3. Comparator: low or no consumption of
sugar-sweetened beverages.
4. Outcome: incident T2D.Definition clearly excludes
artificially-sweetened beverages.
EPIC [29]: Sugar-sweetened carbonate/soft/isotonic drinks and
diluted syrups: 1 glass approximately 8.8 oz serving
HPFS [34]: Sugar-sweetened colas, other carbonated & non-
carbonated beverages (fruit punches, lemonades, or other fruit
drinks). Serving size = standard glass, can, or bottle.
Jfact [48]: Regular soft drinks, sugar-sweetened soda, sports d
excluding 100% juice: 1 glass approximately 250 mL.
NHS [35]: Sugar-sweetened carbonated beverages; did not incl
fruit drinks or uncarbonated SSB. Serving size = a standard gla
can or bottle.
BWHS [28]: Regular soft drinks (not diet soda). Other fruit ju
fortified fruit drinks and Kool-aid assessed separately, 
serving approximately 12 oz. 
NHSII [41]: Coke, Pepsi or other cola with sugar, carbonated 
beverage with sugar, frequency of a "common portion". 
ARIC [44]: Fruit punch, non-diet soda, orange and grapefruit 
frequency of a 1 cup (8 oz) serving. 
MESA [45]: Regular soft drinks, sweetened mineral water (no
non-alcoholic beer, serving size not specified. 
SSB, plus… (2 cohorts)
SSB, not 100% juice (3 Cohorts)





Figure 2 Step 1: Categorizing cohorts according to the definition of the
Risk in Communities Study; BWHS, Black Women's Health Study; EPIC, Europea
Mobile Clinic Heath Examination Survey; HPFS, Health Professional's Follow up
Health Centre-based Prospective Study; MESA, Multi-Ethnic Study of Atherosc
SD, soft drink; SSB, sugar-sweetened beverage.Step 1: Assessing diversity across selected studies for each
participants, exposure/intervention, comparator, and
outcome element
Evidence maps were used to categorize studies based on
the definition of the exposure variable, outcome, and popu-
lation characteristics. Exposure characterization took into
account the type of beverage, data collection instruments,
and frequency/timing of data collection (Figure 2). Variation
in definitions of T2D was evaluated based on criteria for
diagnosis and method of ascertainment such as by a phys-
ician or self-report. Using the study as the unit of analysis,
univariate statistics (n, median, proportion, range) were
used to describe across included cohorts heterogeneity of
SSB intake (exposure and comparator), T2D diagnosis (out-
come), and the following population/study characteristics:
study location, gender, study size, duration of follow-up,
baseline BMI, and baseline SSB consumption.
Step 2. Describing design features and population
characteristics associated with the exposure across
eligible cohorts
Cohorts were organized in a diagram according to category
of the sweetened beverage consumption identified in
Step 1. Design and population characteristics for cohorts     Inclusion of artificially-sweetened
     beverages cannot be ruled out.
serving size.
 artificially-sweetened. Serving size not specified.
FMC [47]: SD, NOS; g/day. No details 








SCHC [42]: SD, NOS measured in glasses of 
intake: investigators expected heterogeneity of 
JPHC [37]: Colas and fruit drinks, sugar and
utated for
All soft drinks (SD)
3 cohorts
study variable, sugar-sweetened beverages. ARIC, Atherosclerosis
n Prospective Investigation of Cancer (InterAct Study); FMC, Finnish
Study; Jfact, Study of Japanese factory workers; JPHC, Japan Public
lerosis; NHS, Nurse's Health Study; SCHS, Singapore Chinese Health Study;
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provided an organized illustration of whether specific defi-
nitions of SSB tended to aggregate with specific study
design features or population characteristics (Figure 3).
Step 3. Describing modeling strategies across eligible
cohorts (assessing confounding)
Evidence-based mapping visually displayed the patterns
of covariates adjusted for in each model of SSB and T2D
as reported by each publication (Figure 4). A check denoted
adjustment for covariates age, smoking, physical activity,
family history, alcohol intake, diet quality score, energy
intake, and body mass index. Overall and within import-
ant strata of the study variable, diversity of multivariableDefinition clearly excludes
artificially-sweetened beverages.
US (6): multi-ethnic cohortsARIC, MESA
Europe (1): eight countries
Japan (1)
Once (4)
Twice: 6 y interval (1)
Every 4 y (3)
<10 (4)
10 to 19 y (2)
20 to 24 y (2)
<24 (1)
24 to 26 (4)
>26 (3)
% reporting ≥1 serving/d: 
   10% or fewer (2) 
   Between 11 to 15% (3) 
   More than 15% (2) 
   Not reported (1)
SSB, Not 100% Juice (3 Cohorts)
Cohort: EPIC [29] H
Cases (T2D): 11,684Reg 2
Maximum follow-up: 16 y
Beverage assessments: Once (BL) E
Highest consumption category: ≥1 serving/d: 8% 4.5 se
7
SSB, Minus… (3 Cohorts)
Cohort: NHS [35] BW
Cases (T2D): 7370SR, W 2
Maximum follow-up: 24 y
Beverage assessments: Every 4 y Twice
Highest consumption category: NR ≥1 se
Definition: Sugar-sweetened Sepa
carbonated beverages for 
SSB, Plus… (2 Cohorts)
Cohort: ARIC [44] M
Cases (T2D): 1437Ex
Maximum follow-up: 9 y
Beverage assessments: Once (BL) O
Highest consumption category: ≥1 serving/d: 17% ≥1 se
men, 13% women


















Figure 3 (Step 2). Sweetened beverage definitions by cohort descript
diagnosed by self-report of symptoms/medication or physician diagnosis (S
baseline; M, men; W, women; ARIC, Atherosclerosis Risk in Communities Stu
Investigation of Cancer (InterAct Study); FMC, Finnish Mobile Clinic Heath E
study of Japanese factory workers; JPHC, Japan Public Health Centre-based
Nurse's Health Study; SCHS, Singapore Chinese Health Study; SD, soft drinkmodeling strategies was described by summarizing opera-
tionalization of the SSB intake (n, percent), the maximum
number of models of SSB and T2D presented in the ori-
ginal publication (median, range), the maximum number of
covariates in models (median, range), and the maximum
change in SSB-T2D risk estimate from the age-adjusted risk
estimate (median, range).
Summarization of evidence-based mapping efforts (Table 2)
Using cohorts as the unit of analysis, for categories
defined by SSB-intake (as determined by Step 1), the
following was tabulated: the diversity of design and
population characteristics, the study variable and the
outcome (as determined in Steps 1 and 2: n, percent),     Inclusion of artificially-sweetened
     beverages cannot be ruled out.
Finland (1): 177 casesReg, enrolled 1976-72, FMC [47]
One (3)
10 to 12 y (3)
<24 (2)
24 to 26 (0)
>26 (1)FMC (47)
Low overall consumption:
    mean aoproximately 0.2 servings/d (1)FMC [47]
≥2 glasses/wk (1)SCHS [42]: 10.6%
≥1 serving/d (1)JPHC [37]: 9% men, 5% women
PFS [34] Jfact [48]
680SR, M 170Ex, M
20 y 7 y
very 4 y Once (BL)
rvings/wk to ≥1 serving/d: 12%
.5/d: 25%
HS [28] NHSII [41]
713SR, W 741SR, W
10 y 8 y
: 6 y interval Twice: every 4 y
rving/d: 17% ≥1 serving/d: 9.5%
rate analysis Sugar-sweetened











China (1): 2,273 T2D casesSR, SCHS [42]
Japan (1): 824 T2D casesSR, JPHS [37]
ge)
fined
All soft drinks (SD)
(3 cohorts)
ion and methods: studies of incident type 2 diabetes (T2S). T2D
R); linkage to a registry (Reg); or upon exam (Ex). NR, not reported; BL,
dy; BWHS, Black Women's Health Study; EPIC, European Prospective
xamination Survey; HPFS, Health Professional's Follow up Study; Jfact,
Prospective Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS,
; SSB, sugar-sweetened beverage.
Figure 4 (Step 3). Covariates adjusted for in multivariable models of sugar-sweetened beverages and type 2 diabetes: 11 cohorts. 1.
Calculated as proportion change from the age-adjusted model or a fairly simple model: (RRage adjusted - RRmodel)/(RRage adjusted - 1). ↑ denotes
an increase in the risk estimate. 2. For the MESA cohort, the model information was based on author correspondence reported in a 2010 meta-analysis
[50]. BL, adjustment variable based on baseline assessment. All cohorts used Cox proportional hazards models, except JPHC [37], which used
logistic regression.
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Table 2 Design heterogeneity across 11 cohorts assessing risk of type 2 diabetes, stratified by inclusion of artificially





Study design and population and characteristics N % n %
Study location
United States 6 75% 0
Europe 1 13% 1 33%
Japan 1 13% 2 67%
Gender
Women 3 38% 0
Men 2 25% 0
Both men and women 3 38% 3 100
Case of T2D
1 to 4,999 2 25% 1 33%
500 to 4,999 4 50% 2 67%
5,000+ 2 25% 0
Duration of follow-up
<10 years 4 50% 0
10 to 14 years 1 13% 3 100%
15+ years 3 38% 0
Mean baseline body mass index (kg/m2)
<24 1 13% 2 67%
24 to 26 4 50% 0
>26 3 38% 1 33%
Number/timing of beverage assessment
Once at baseline (study length range from 7 to 16 years) 4 50% 3 100%
Twice (6-year interval) 1 13% 0
Every 4 years 3 38% 0
Proportion of study participants reporting≥ serving/day
10% or fewer or low consumption 2 25% 3 100%
Between 11 and 15% 3 38% 0
More than 15% 2 25% 0
Not reported 1 13% 0
Method of type 2 diabetes (T2D) diagnosis
Self report with validation 4 50% 2 67%
Direct measurement/medical records 4 50% 1 33%
Operation of study variable in multivariable models: highest versus lowest category of consumption
Highest consumption category:
2+ drinks or cups/dayARIC,BWHS 2 25% 0 33%
1+ glasses or servings/day 6 75% 1 67%
<1 serving/day 0 2
Lowest consumption category:
Never 2 25% 1 33%
never or rarely 5 63% 2 67%
<1 cup/dayARIC 1 13% 0
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Table 2 Design heterogeneity across 11 cohorts assessing risk of type 2 diabetes, stratified by inclusion of artificially
sweetened beverages in the study variable definition (Continued)
Characterization of multivariable models Range Median Range Median
No multivariable models presented 1 to 8 4 2 to 4 3
Maximum number of co-variables in multivariable modelsa 9 to 17 14 14 to 17 15
Maximum% change in SSB-T2D risk from age-adjusted estimate 46 to 95% 61% 2 to 26% 18%
aCovariates most frequently adjusted for in multivariable models of the 11 eligible cohorts include physical activity (11 of 11), smoking (11), energy intake (11),
BMI (10), family history (9), alcohol intake (8), education (5), and diet quality score (4).
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(Step 3: n, percent), the number of multivariable models
of SSB-T2D presented in the original publication (Step 3:
median, range), the number of covariates in SSB-T2D
multivariable models (Step 3: median, range), and the
change in SSB-T2D risk estimate from the age-adjusted
risk estimate (Step 3: median, range).Results
Literature search and identification of eligible publications
The search results are summarized in Figure 1. Briefly, a
total of 3,148 titles were reviewed (2,005 from Pubmed and
1,143 from Scopus). After duplicate removal (N = 180),
2,968 titles were examined and reviewed in a two-step
process. We identified 146 titles broadly on topic; a second
review revealed that 90 were prospective epidemiology
studies, commentary and reviews of sugar and T2D.
Excluded were publications whose focus was not dietary
sugar intake and T2D and those that were case–control,
cross-sectional and ecologic studies (N = 56). Full-text
review of the 90 publications identified 22 primary re-
search publications of the relationship between dietary
sugar intake and T2D [28-49] and one meta-analysis with
previously unpublished data [50]. A bibliography search of
systematic reviews and meta-analyses did not identify any
more potentially eligible titles [50-52].
Table 1 summarizes 21 publications from 17 cohorts that
report the relationship between the following measures
of dietary sugar intake and T2D [28-48]: category of SSB
(broadly defined including some studies which include
both artificially and sugar-sweetened beverages) and sugar-
related macronutrients (total sugars, sucrose, fructose, and
glucose). Studies of SSB (broadly defined) represent the
majority of the published work on measures of dietary
sugar intake, with 15 publications from 11 cohorts, most
with more than 5,000 study participants. Nine publications
from eight cohorts analyze sugar-related macronutrients
and T2D, with total sugars and sucrose being the most
frequently assessed. With the exception of a Finnish
study initiated prior to 1970, all studies of macronutrients
have >25,000 participants. A very small Swedish study
assessing cake and biscuit consumption [49] was not
summarized by Table 1.Organizing and evaluating design heterogeneity among
cohorts assessing sugar-sweetened beverages and type 2
diabetes
For the assessment of design heterogeneity, we selected
one publication from each cohort that had multiple pub-
lications (n = 3 cohorts). We selected the one in which
SSB was either the main study variable or the definition
was the clearest. Details of unselected publications are
noted at the bottom of Figure 1.
Step 1. Assessing diversity across selected studies for each
participants, exposure/intervention, comparator, and
outcome element
Study variables and outcomes were categorized into logical
groups by definitions reported in each of the 11 eligible
cohorts. No two cohorts define the main study variable
alike. As shown in Figure 2, two broad definitions of sweet-
ened beverage consumption emerged: 1) three studies used
the nonspecific definition soft drinks (SD) that included
both sugar and artificially-sweetened beverages, and 2)
eight studies restricted the definition to SSB only. Three
distinct subgroups were identified among cohorts defining
the study variable as exclusively sugar-sweetened. The gen-
eral definition ‘SSB, not 100% juice’ includes all drinks with
added sugar (sodas, colas, other carbonated SSB, and non-
carbonated SSBs such as fruit punches, lemonades or other
fruit drinks). Two other SSB patterns were identified within
the remaining five cohorts based on whether they excluded
beverages (SSB minus, three cohorts) or included additional
beverages (SSB plus, two cohorts) from the anchor defin-
ition (SSB, not 100% juice). We found that investigators
more frequently excluded beverages from the anchor defin-
ition, most broadly noncarbonated soft drinks as an entire
group or fruit drinks. Two studies added beverages to the
definition, one orange and grapefruit juice and the other
non-alcoholic beer. This detailed characterization of the
study variable identified two broad research questions
addressed by this series of selected studies: T2D risk asso-
ciated with intake of 1) SSB only or 2) any SD (artificially or
sugar-sweetened).
Of the 11 cohorts, method of diagnosis was based on
self-report (n = 6; 3 of the 6 were studies of health pro-
fessionals), registry linkage (n = 2), and an examination by
a health professional (n = 3).
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characteristics across the 11 cohorts revealed heterogeneity
in study location (US: n = 6, Europe: n = 2, China/Japan:
n = 3), size (>5000 cases: n = 2, 500 to 4999 cases: n = 6,
1 to 499 cases: n = 3), duration of follow-up (<10 years:
n = 4, 10 to 14 years: n = 4, 15 or more years: n = 3); mean
baseline body mass index (<24 kg/m2: n = 3, 24 to 26 kg/m2:
n = 4, > 26 kg/m2: n = 4), ascertainment of diet (food
frequency questionnaire: n = 8, diet history: n = 3), and
frequency of diet assessment (baseline only: n = 7, twice
every 6 years: n = 1, every 4 years: n = 3). We also found a
relatively low consumption of SSB across the 11 cohorts
with nearly half (n = 5) reporting that 10% or fewer partici-
pants consumed one or more servings per day.
Step 2. Describing design features and population
characteristics associated with the study variable across
eligible cohorts
The upper portion of Figure 3 compares design features and
population characteristics of cohorts defining sweetened
beverage consumption as SSB only and SD. SSB cohorts
were mainly US-based (n = 6), completed diet assessments
at least twice (n = 4), followed subjects for fewer than 10
years (n = 4), and reported a mean body mass index (BMI)
≥24 kg/m2 (n = 7). We identified three levels of SSB con-
sumption ascertained at the baseline visit of these eight
combined cohorts: frequency of one or more servings a day
(highest consumption group for each study) was reported by
10% or fewer (n = 2), between 11 and 15% (n = 3) and more
than 15% (n = 2) of cohort participants.
Design and population characteristics for SD cohorts
presented differently. Two of three SD cohorts were Asian
populations; the one western population was a small
Finnish study that enrolled participants between 1967
and 1972. Mean BMI was <24 kg/m2 in two of the three
studies, SD consumption was measured only at the base-
line visit (10 to 12 years prior to maximum follow-up
duration), and SD consumption overall for the three
cohorts was low. Comparison of the study design fea-
tures of cohorts assessing SSB only with SD suggests it
would not be sensible to combine all eleven studies in a
meta-analysis; instead the main pooled analysis should
include the eight SSB-only studies.
Further division of SSB cohorts into categories of SSB,
SSB minus, and SSB plus uncovered patterns according to
study design, as shown in the lower portion of Figure 3.
Large studies of women (Black Women’s Health Study
(BWHS), Nurse’s Health Study (NHS), NHSII) with mul-
tiple dietary assessments more narrowly defined SSB con-
sumption as excluding noncarbonated drinks (SSB, minus).
The multicultural cohorts initiated to study atherosclerosis
(Multi-Ethnic Study of Atherosclerosis (MESA), Athero-
sclerosis Risk in Community study (ARIC)) more broadly
defined SSB by including either juice or non-alcoholic beer.These cohorts have higher baseline SSB consumption when
compared to studies defining SSB more narrowly. No clear
pattern emerged for cohorts defining the study variable as
SSB, not 100% juice. Stratification of a meta-analysis on
SSB subcategories and gender may additionally be important
for understanding pooled T2D risk estimates.
We used a similar process to evaluate design hetero-
geneity of the outcome definitions used in these cohorts.
While several different criteria for T2D were used in the
11 cohorts, the main defining characteristic was whether
the diagnosis was based on self-report (all included a
validation study), physical examination, or linkage to a
registry or other health database. With the exception of
the European Investigation of Cancer (EPIC) study, which
verified cases via a registry, the larger studies (>25,000
participants) relied on self-reported diagnoses. Three studies
conducted routine physical exams.
Step 3. Diversity of modeling strategies (confounding)
Multivariable models compared risk in the highest category
of consumption (quartile or quintile) to the lowest. Figure 4
summarizes the different definitions of high and low
categories of sweetened beverage consumption. Among
studies of SSB only, the highest consumption category was
1+ glasses or servings each day in 6 (of 8) cohorts and
2+ drinks or cups each day for 2 (serving sizes varied). In
comparison, the highest consumption category for two of
three cohorts evaluating SD was less than one serving per
day. Never or rare sweetened beverage consumption was
the most frequently employed reference group (7 of 11),
followed by never consumption (3 of 11). ARIC was the
only study to include more frequent consumption in
the reference group: up to one cup of SSB per day.
Figure 4 visually depicts multivariable models and the
pattern of covariate adjustment across 11 cohorts. The
majority of cohorts present a multivariate model adjusting
for age, physical activity, smoking, family history, alcohol
intake, energy intake and BMI. Four studies adjust for a diet
quality score, although all measure and adjust for some
aspect of diet. Many models further adjust for multiple
other covariates (up to 17).
Many models use different definitions to adjust for the
listed co-variables and 9 of 11 adjust for covariates as
measured at baseline. For example, measures of other
dietary factors ranged from one variable measuring dietary
fiber to healthy eating scores based on the entire diet (for 3
cohorts only). Likewise body mass index is adjusted in
many ways: as a continuous variable (3 of 11 cohorts), a
categorical variable (5 of 11 cohorts), and as measured at
baseline (6 of 11 cohorts).
Multivariable models adjust for between 5 and 17 covari-
ates which corresponded to a 46% to 95% maximum reduc-
tion from the age-adjusted model in T2D risk associated
with SSB-only intake (Figure 4). Change in the risk estimate
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women using sugar-sweetened carbonated beverages as the
study variable: reductions were as large as 95% in the
BWHS, 61% in the NHS, and 67% in the NHSII. Change
in risk estimates with addition of covariates was less
pronounced among SD cohorts (range, 2-26%).Summarization of evidence-based mapping efforts
Table 2 concisely summarizes the considerable amount of
variability in study design, population characteristics, and
statistical analysis among the 11 cohorts of sweetened
beverages and T2D. This table represents a proto-type for a
universal table on study design heterogeneity summarizing
key design features uncovered by detailed evidence-based
mapping efforts and organized according to PICO elements.
The results in Table 2 are presented stratified by SSB only
and SD to display the association of different definitions of
the study variable with specific design and population char-
acteristics. In addition, Table 2 highlights diversity in statis-
tical analysis and provides a benchmark for the potential for
confounding overall and for the two primary definitions of
sweetened beverage consumption.Discussion
Evidence-based mapping can be used as a tool to improve
the assessment and reporting of design heterogeneity prior
to meta-analysis of epidemiologic studies. The framework
described herein is useful for all study designs, but par-
ticularly for observational epidemiologic studies, which
are complex and rich in important detail. If studies are
found to be similar enough to combine via meta-analysis,
this framework is useful for evaluating diversity in study
designs, particularly statistical methods; facilitating the lo-
gical categorization of studies for stratified and sensitivity
analyses when designing a protocol or analysis plan for a
meta-analysis; and developing tools for model selection in
meta-analysis of observational studies reporting multiple
multivariable models. A standard table for summarizing
the results from the 3 steps in this framework is essential
for displaying the multi-dimensionality of diversity across
a group of selected studies and to aid interpretation of a
pooled risk estimate.
Evidence maps are ideal tools for characterizing het-
erogeneity prior to a meta-analysis. Previously they have
been used for research priority setting by the Cochrane
Collaboration [53] and other organizations such as the
Agency for Healthcare Research and Quality [54-56]. In
addition to organizing a complex body of research, another
defining feature of evidence mapping is that the mapping
of study characteristics is undertaken without linking to
study results [15]. Although we used prospective observa-
tional studies of SSB and T2D to explain our approach, the
framework is robust and this strategy can be applied toother exposure-disease relationships and epidemiologic
study types.
The evidence-based mapping strategies using SSB and
T2D as an example facilitated the logical grouping of
studies on key design features and suggested subgroups
of studies appropriate for statistical summation via meta-
analysis. For example, we found considerable variability in
the definition and methods of collection of the exposure
variable (sweetened beverages). Most notable is the inclu-
sion of artificially-sweetened beverages in the definition in
3 of 11 cohorts. Consequently two broad research ques-
tions are addressed by this series of selected studies: T2D
risk associated with intake of 1) SSB only and 2) any soft
drink (artificially or sugar-sweetened). Diversity across
studies in the definition of the exposure variable may be
due to a combination of factors, including availability of
data from the dietary assessment tool, the definition used
by the study investigators, or the level of detail provided
in the publication. Improving the interpretability of meta-
analyses will require investigators of primary studies, in as
much as possible, to define variables, conduct analyses,
and report findings with an eye towards how their results
may be compared to or possibly combined with other
studies in the future.
The systematic approach described herein culminated
in a prototype for a table that can be employed widely
for reporting the extent and multi-dimensional nature of
design heterogeneity across eligible studies in a meta-
analysis. This table is recommended in addition to the
classic table 1 in a systematic review (which usually de-
scribes studies individually). A standard table summarizing
design heterogeneity across all selected studies will bring to
the fore many elements necessary for interpreting the
pooled risk estimate from a meta-analysis. One of many
examples from our assessment of cohorts of SSB and T2D
is 7 of 11 studies measured beverage intake only once
at baseline, each using a different diet questionnaire and
following participants for T2D from 7 to 16 years. The
etiologically relevant time period for most chronic diseases,
including T2D, is most often not known, and a one-time
measurement of dietary intake may not capture intake in
the relevant time frame. This is a fundamental consider-
ation when interpreting results of chronic disease studies,
including meta-analysis of these data.
To our knowledge, this may be the first detailed report
of diversity of statistical modeling approaches among
observational studies selected for a meta-analysis. A com-
mon practice for reporting modeling strategies in meta-
analyses of observational studies is to provide a list of
included covariates by study. We suggest summarizing
the following across selected studies: the number of
multivariable models presented, the number of covariates
adjusted for in multivariable models, and the fluctuation in
the fully adjusted risk estimate relative to the age-adjusted
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may add confidence about the results of a meta-analysis
combining models that all adjust for the same 5 variables
and with little fluctuation in the most fully adjusted risk
estimate compared to the age or most minimally adjusted
model. In contrast, cohorts of SSB and T2D reported up
to 8 multivariable models adjusting for between 11 and 17
covariates. The results revealed a 2-95% reduction in risk
of T2D associated with sweetened beverage consumption
in fully adjusted relative to minimally/age- adjusted
models (Table 2). The latter finding was most pronounced
among the eight studies of SSB only, where adjustment
for between 11 to 17 covariates resulted in a 46 to 95%
reduction in the SSB-T2D risk estimate (Table 2). In
other words, in many studies adjustment for covariates
explained half to all of the association between SSB and
T2D and should be considered when analyzing and
interpreting a meta-analysis of the data.
Selection of statistical models by the study investigators
from the primary publication and by a review investigator
for a meta-analysis also influences the final outcome of a
pooled analysis of observational studies. This particular
bias, called selective analysis reporting, has recently been
discussed as a major concern for meta-analysis of non-
randomized studies, but also applies to observational
etiologic investigations [57]. Covariate selection and mod-
eling strategies require careful consideration in the final
interpretation of a pooled analysis of SSB and T2D; a
single estimate for a pooled risk may be an oversimplifica-
tion of complex data. Evidence maps can help facilitate
the selection of additional models for sensitivity analyses
in a meta-analysis.
Heterogeneity of studies can be a reason not to perform
a meta-analysis. For example, a systematic review of whole
grain foods and T2D that had intended to complete a
meta-analysis concluded a qualitative synthesis was more
appropriate for the data [58]. Other investigators have
determined that a meta-analysis of this topic was inform-
ative [59,60]. A tool (such as the proposed summary table)
that clearly displays design heterogeneity may be helpful
in weighing both sides of this type of debate.
Systematic reviews and meta-analyses are well accepted
research synthesis methods that serve to inform re-
searchers, policy makers and, increasingly, the public of
the potential causes of disease and the extent to which
disease (or preventive) interventions are effective. The
efficiency of these efforts depends largely on the quality
of data from primary studies and a clear assessment of
the extent to which that data can be combined.
Conclusions
We illustrate a framework employing evidenced-based
mapping to organize, evaluate and document design het-
erogeneity. This exercise culminated in a recommendationfor a standardized table format that clearly summarizes
design heterogeneity of eligible studies, with the goal of
informing a protocol for meta-analysis and subsequently
facilitating interpretation of summary risk estimates after
quantitative synthesis. We recommend expanding the
practice of meta-analysis of cohort studies to include a
standard table that summarizes design heterogeneity.
Addition of this table to reporting of meta-analyses
provides the reader with more evidence to interpret the
summary risk estimates.
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